SAN DIEGO — Patients with COPD treated with targeted lung denervation along with optimal COPD therapy experienced fewer exacerbations over 2 years, according to research presented at the American Thoracic Society International Conference.Targeted lung denervation (Nuvaira Inc.) has “only [been] done in research setting to date,” Gerard J. Criner, MD, FACP, FACCP, chair and
The findings dash hopes that antimicrobials would benefit patients with life-threatening idiopathic pulmonary fibrosis. The trial, however, will still benefit the battle against the deadly lung disease, the researchers say.
The findings dash hopes that antimicrobials would benefit patients with life-threatening idiopathic pulmonary fibrosis. The trial, however, will still benefit the battle against the deadly lung disease, the researchers say.